| Market cap | $57.44M |
|---|---|
| Enterprise value | N/A |
| Revenue | N/A |
|---|---|
| EBITDA | N/A |
| Income | -$8.31 |
| Revenue Q/Q | N/A |
| Revenue Y/Y | N/A |
| P/E | 0.00 |
|---|---|
| Forward P/E | N/A |
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | 0.43 |
| PEG | N/A |
| Price/Sales | 786.89 |
| P/FCF | N/A |
| Price/Book | 3.46 |
| Book/Share | 0.02 |
| Cash/Share | N/A |
| FCF yield | -37.07% |
| Volume | 8.383M / 36.438k |
|---|---|
| Relative vol. | 230.07 × |
| EPS | N/A |
|---|---|
| EPS Q/Q | -99.00% |
| Est. EPS Q/Q | 384.00% |
| Profit margin | N/A |
|---|---|
| Oper. margin | -25,071.23% |
| Gross margin | N/A |
| EBIT margin | -11,424.66% |
| EBITDA margin | -28,224.66% |
| Ret. on assets | -36.48% |
|---|---|
| Ret. on equity | -50.31% |
| ROIC | -28.96% |
| ROCE | -52.53% |
| Debt/Equity | N/A |
|---|---|
| Net debt/EBITDA | 2.39 |
| Current ratio | 4.11 |
| Quick ratio | 4.11 |
| Volatility | 24.69% |
|---|---|
| Beta | 0.00 |
| RSI | 40.18 |
|---|
| Insider ownership | 11.07% |
|---|---|
| Inst. ownership | 17.29% |
| Shares outst. | 7.376M |
|---|---|
| Shares float | 0.000 0.00% |
| Short % of float | 2.44% |
| Short ratio | 0.53 |
| Dividend | $0.00 |
|---|---|
| Dividend yield | 0.00% |
| Payout ratio | N/A |
| Payment date | N/A |
| Ex-dividend date | N/A |
| Earnings date | N/A |
Friday, 6 May 2022
|
|
| PolarityTE to Report Q1 2021 Financial Results on May 16, 2022 | |
Wednesday, 13 April 2022
|
|
| Healthcare Breakthroughs: Atai, Nova Mentis, PolarityTE, and LIXTE; Biomed Leaders Report Latest Advances in Regenerative Tissue Technology, Psychedelics, and New Therapeutics for Autism, Mental Health and Cancers - Yahoo Finance | |
Tuesday, 12 April 2022
|
|
| BioMed Stocks On the Move: Nova Mentis, PolarityTE, Biodesix and PharmaDrug; Life Sciences Leaders Report Latest Advances in Regenerative Tissue Technology, New Drugs for Cancers, Glaucoma, and Autism, and Diagnostics. - Yahoo Finance | |
Wednesday, 30 March 2022
|
|
| PolarityTE Reports Fiscal Year 2021 Financial Results and Provides Business Update | |
Wednesday, 16 March 2022
|
|
| PolarityTE Announces $5.0 Million Registered Direct Offering | |
Monday, 22 November 2021
|
|
| UPCOMING DEADLINE REMINDER: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against PolarityTE, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm | |
Friday, 19 November 2021
|
|
| PTE FINAL DEADLINE TUESDAY: ROSEN, A GLOBAL AND LEADING LAW FIRM, Encourages PolarityTE, Inc. Investors to Secure Counsel Before Important November 23 Deadline in Securities Class Action - PTE | |
| DEADLINE TUESDAY REMINDER: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against PolarityTE, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm | |
Tuesday, 16 November 2021
|
|
| ROSEN, A LEADING AND TOP RANKED LAW FIRM, Encourages PolarityTE, Inc. Investors with Losses to Secure Counsel Before Important November 23 Deadline in Securities Class Action - PTE | |
Wednesday, 10 November 2021
|
|
| POLARITYTE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against PolarityTE, Inc. and Encourages Investors to Contact the Firm | |
Thursday, 28 October 2021
|
|
| PolarityTE to Report Third Quarter Financial Results on November 10, 2021 | |
Tuesday, 19 October 2021
|
|
| ROSEN, A LEADING LAW FIRM, Encourages PolarityTE, Inc. Investors to Secure Counsel Before Important November 23 Deadline in Securities Class Action - PTE | |
Saturday, 9 October 2021
|
|
| ROSEN, A LEADING LAW FIRM, Encourages PolarityTE, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action – PTE | |
Monday, 4 October 2021
|
|
| INVESTOR ACTION REMINDER: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against PolarityTE, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm | |
Monday, 27 September 2021
|
|
| POLARITYTE ALERT: Bragar Eagel & Squire, P.C. Announces That a Class Action Lawsuit Has Been Filed Against PolarityTE, Inc. and Encourages Investors to Contact the Firm | |
Wednesday, 28 July 2021
|
|
| SkinTE® Met Primary and Secondary Endpoints in Final Analysis from Diabetic Foot Ulcer Trial | |
Monday, 26 July 2021
|
|
| PolarityTE Submits Investigational New Drug Application for SkinTE® in Chronic Cutaneous Ulcers | |
Friday, 16 July 2021
|
|
| PolarityTE Issues Statement About Potential Ticker Symbol Confusion | |
Monday, 12 July 2021
|
|
| PolarityTE Receives Notice of Allowance for Chinese Patent | |
Thursday, 13 May 2021
|
|
| PolarityTE Reports First Quarter Results and Provides Business Update | |
Monday, 10 May 2021
|
|
| PolarityTE Announces Diabetic Foot Ulcer Trial Met Primary and Secondary Endpoint | |
Monday, 3 May 2021
|
|
| PolarityTE to Report First Quarter Financial Results on May 13, 2021 | |
Tuesday, 30 March 2021
|
|
| PolarityTE Reports Fourth Quarter and Fiscal Year 2020 Results | |
Wednesday, 10 March 2021
|
|
| PolarityTE to Report Fiscal Year 2020 Financial Results on March 30, 2021 | |
| Insider |
Trans.
Transaction
|
Total value |
|---|---|---|
| Chris Nolet Director | Option 12 Jan 2023 | $28,833 |
| Peter A Cohen Director | Sale 17 Aug 2022 | $10,950 |
| Peter A Cohen Director | Sale 16 Aug 2022 | $20,091 |
| David B Seaburg Director | Sale 19 Oct 2021 | $17,070 |
| David B Seaburg Director | Option 1 Sep 2021 | $565,599 |
| Richard Hague Chf. Exec. Off. and Pres. | Sale 9 Aug 2021 | $8,473 |
| David B Seaburg Director | Sale 16 Jul 2021 | $22,033 |
| Richard Hague Chf. Exec. Off. and Pres. | Sale 16 Jul 2021 | $8,946 |
| Richard Hague Chf. Exec. Off. and Pres. | Sale 29 Jun 2021 | $6,437 |
| Peter A Cohen Director | Buy 18 May 2021 | $259,700 |
| David B Seaburg Director | Sale 19 Apr 2021 | $26,997 |
Powered by
Robintrack.
Price target
Current $0.24
Average $3.00
Low $3
High $3
Dividends
| Ex-dividend date | N/A | Frequency | Irregular | Annual dividend | +0.00% |
|---|---|---|---|---|---|
| Next dividend | N/A | Dividend yield | 0.00% | Growth period | N/A |
| Last dividend date | Yield 3 years | 0.00% | Growth 3 years | +0.00% | |
| Last dividend | Yield 5 years | 0.00% | Growth 5 years | +0.00% |
| Insider | Age | Since | Compensation |
|---|---|---|---|
| Richard Hague (61) Pres and CEO | 61 | $649,256 | |
| Cameron J. Hoyler (37) Gen. Counsel, Sec., Exec. VP of Corp. Devel., and Strategy | 37 | $623,192 | |
| Daniel Gasiorowski | |||
| Wladyslaw Zmuda | 2020 | ||
| Michal Zadlo | 2020 | ||
| Beata Sobocinska | 2020 | ||
| Kamila Krawiec | 2018 | ||
| Michal Herominski | 2018 | ||
| Patryk Gall | 2020 | ||
| Emil Cybulski | 2017 | ||
| Pawel Cieslik | 2018 | ||
| Maria Biernacik-Bankowska | 2018 | ||
| Agnieszka Kosno | |||
| Zbigniew Stawinoga | 2018 | ||
| Rafal Markiewicz | 2018 | ||
| Mark E. Lehman J.D. | |||
| Ryan Mathis M.D. | |||
| Dr. Jon Anthony Joseph Burrows B.Sc., M.Sc., Ph.D. (58) Sr. VP of Corp. Devel. and Pres of Contract Services | 58 | ||
| Dr. Stephen Milner M.D., DDS, DSc, FRCSE, FACS (72) Chief Clinical Officer and Member of Clinical Advisory Board | 72 | ||
| Alain Adam | |||
| Angela Ziegler | |||
| Rich Haerle | |||
| Nikolai Sopko | |||
| Jacob Alexander Patterson (42) Chief Financial Officer | 42 |
polarityte, inc. (nasdaq: cool) is the owner of a novel regenerative medicine and tissue engineering platform developed and patented by denver lough md, phd. this radical and proprietary technology employs a patients' own cells for the healing of full-thickness functionally-polarized tissues. if clinically successful, the polarityte platform will be able to provide medical professionals with a truly new paradigm in wound healing and reconstructive surgery by utilizing a patient's own tissue substrates for the regeneration of skin, bone, muscle, cartilage, fat, blood vessels and nerves. it is because polarityte uses a natural and biologically sound platform technology, which is readily adaptable to a wide spectrum of organ and tissue systems, that the company and its world-renowned clinical advisory board, are poised to drastically change the field and future of translational regenerative medicine. more info can be found online at www.polarityte.com welcome to the shift™
- Health Care > Biotechnology
- PolarityTE Inc, 1960 South 4250 West, Salt Lake City 84104, United States
- 800 560 3983
- Investor relations
Dividends
| Ex-dividend date | N/A | Frequency | Irregular | Annual dividend | +0.00% |
|---|---|---|---|---|---|
| Next dividend | N/A | Dividend yield | 0.00% | Growth period | N/A |
| Last dividend date | Yield 3 years | 0.00% | Growth 3 years | +0.00% | |
| Last dividend | Yield 5 years | 0.00% | Growth 5 years | +0.00% |
Quarterly EPS estimates
Profit margin
Debt to assets
Cash flow
Balance sheet
XSLX
| (in millions USD) | 31 Mar 2023 | 31 Dec 2022 | |||
|---|---|---|---|---|---|
| Current assets | |||||
| Cash | $6.394 | $11.446 | |||
| Short term investments | |||||
| Net receivables | |||||
| Inventory | |||||
| Total current assets | $8.927 | $13.255 | |||
| Long term investments | |||||
| Property, plant & equipment | $8.211 | $8.681 | |||
| Goodwill & intangible assets | |||||
| Total noncurrent assets | $9.122 | $9.592 | |||
| Total investments | |||||
| Total assets | $18.049 | $22.847 | |||
| Current liabilities | |||||
| Accounts payable | $1.714 | $1.38 | |||
| Deferred revenue | |||||
| Short long term debt | |||||
| Total current liabilities | $2.172 | $2.067 | |||
| Long term debt | $2.495 | $2.673 | |||
| Total noncurrent liabilities | $3.456 | $4.162 | |||
| Total debt | $2.495 | $2.673 | |||
| Total liabilities | $5.628 | $6.229 | |||
| Stockholders' equity | |||||
| Retained earnings | -$520.474 | -$516.231 | |||
| Other stockholder equity | |||||
| Total stockholder equity | $12.421 | $16.618 | |||
| (in millions USD) | 2022 | 2021 | ||
|---|---|---|---|---|
| Current assets | ||||
| Cash | $11.446 | $19.375 | ||
| Short term investments | ||||
| Net receivables | $0.978 | |||
| Inventory | ||||
| Total current assets | $13.255 | $22.389 | ||
| Long term investments | ||||
| Property, plant & equipment | $8.681 | $8.069 | ||
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $9.592 | $8.789 | ||
| Total investments | ||||
| Total assets | $22.847 | $31.178 | ||
| Current liabilities | ||||
| Accounts payable | $1.38 | $3.115 | ||
| Deferred revenue | $0.074 | |||
| Short long term debt | ||||
| Total current liabilities | $2.067 | $4.709 | ||
| Long term debt | $2.673 | $0.043 | ||
| Total noncurrent liabilities | $4.162 | $7.225 | ||
| Total debt | $2.673 | $0.043 | ||
| Total liabilities | $6.229 | $11.934 | ||
| Stockholders' equity | ||||
| Retained earnings | -$516.231 | -$508.398 | ||
| Other stockholder equity | ||||
| Total stockholder equity | $16.618 | $19.244 | ||
Income statement
| (in millions USD) | 31 Mar 2023 | 31 Dec 2022 | |||
|---|---|---|---|---|---|
| Revenue | |||||
| Total revenue | |||||
| Cost of revenue | |||||
| Gross profit | |||||
| Operating activities | |||||
| Research & development | $2.282 | $2.559 | |||
| Selling, general & administrative | $2.464 | $2.571 | |||
| Total operating expenses | $4.802 | $1.365 | |||
| Operating income | -$4.802 | -$1.365 | |||
| Income from continuing operations | |||||
| EBIT | -$4.274 | -$0.616 | |||
| Income tax expense | |||||
| Interest expense | -$0.031 | -$0.022 | |||
| Net income | |||||
| Net income | -$4.243 | -$0.594 | |||
| Income (for common shares) | -$4.243 | -$0.594 | |||
| (in millions USD) | 2022 | 2021 | ||
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $0.814 | $9.404 | ||
| Cost of revenue | $0.616 | $4.316 | ||
| Gross profit | $0.198 | $5.088 | ||
| Operating activities | ||||
| Research & development | $11.048 | $14.182 | ||
| Selling, general & administrative | $15.027 | $23.284 | ||
| Total operating expenses | $22.571 | $38.774 | ||
| Operating income | -$22.373 | -$33.686 | ||
| Income from continuing operations | ||||
| EBIT | -$7.822 | -$30.06 | ||
| Income tax expense | ||||
| Interest expense | $0.011 | $0.127 | ||
| Net income | ||||
| Net income | -$7.833 | -$30.187 | ||
| Income (for common shares) | -$7.833 | -$30.187 | ||
Cash flows
| (in millions USD) | 31 Mar 2023 | 31 Dec 2022 | |||
|---|---|---|---|---|---|
| Net income | -$4.243 | -$0.594 | |||
| Operating activities | |||||
| Depreciation | $0.148 | $0.276 | |||
| Business acquisitions & disposals | |||||
| Stock-based compensation | $0.046 | $0.268 | |||
| Total cash flows from operations | -$5.08 | -$4.298 | |||
| Investing activities | |||||
| Capital expenditures | $0.1 | $0.058 | |||
| Investments | |||||
| Total cash flows from investing | $0.1 | $0.058 | |||
| Financing activities | |||||
| Dividends paid | |||||
| Sale and purchase of stock | $0.001 | ||||
| Net borrowings | -$0.072 | -$0.409 | |||
| Total cash flows from financing | -$0.072 | -$0.408 | |||
| Effect of exchange rate | |||||
| Change in cash and equivalents | -$5.052 | -$4.648 | |||
| (in millions USD) | 2022 | 2021 | ||
|---|---|---|---|---|
| Net income | -$7.833 | -$30.187 | ||
| Operating activities | ||||
| Depreciation | $1.507 | $2.842 | ||
| Business acquisitions & disposals | $2.327 | |||
| Stock-based compensation | $1.857 | $5.381 | ||
| Total cash flows from operations | -$22.597 | -$22.63 | ||
| Investing activities | ||||
| Capital expenditures | $0.216 | -$0.096 | ||
| Investments | ||||
| Total cash flows from investing | $2.543 | -$0.096 | ||
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $7.826 | $16.613 | ||
| Net borrowings | -$0.337 | -$0.581 | ||
| Total cash flows from financing | $12.125 | $16.579 | ||
| Effect of exchange rate | ||||
| Change in cash and equivalents | -$7.929 | -$6.147 | ||
Recent institutional transactions
| Quarter | Shareholder | Change |
Shares owned
Shares
|
Value (in thousands USD) |
|---|---|---|---|---|
| 2023 Q4 | Fsa Wealth Management |
Opened
|
8 | $0 |
| 2023 Q3 | Strategic Investment Solutions, il |
+6,200.00%
|
2,520 | $191 |
| 2022 Q3 | Millennium Management |
-42.57%
|
20,548 | $18 |
| 2022 Q3 | American Portfolios Advisors |
Opened
|
1 | $1 |
| 2022 Q2 | Citadel Advisors |
Sold out
|
23,792 | $35 |
| 2022 Q1 | American Portfolios Advisors |
Sold out
|
3 | $1 |
Institutional shareholders
| Shareholder | Stake |
Shares owned
Shares
|
Value (in thousands USD) |
|---|---|---|---|
| Citadel Advisors | 0.32% | 23,792 | |
| Millennium Management | 0.28% | 20,548 | |
| Strategic Investment Solutions, il | 0.03% | 2,520 | |
| Game Plan Advisors | 0.00% | 40 | |
| Fsa Wealth Management | 0.00% | 8 | |
| American Portfolios Advisors | 0.00% | 4 |
Sign up